CCO Reading Tools
How to cite item
Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?
Citation Format
ABNT
APA
BibTeX
CBE
EndNote - EndNote format (Macintosh & Windows)
MLA
ProCite - RIS format (Macintosh & Windows)
RefWorks
Reference Manager - RIS format (Windows only)
Turabian
@article{{CCO}{117999}, author = {Hoeh, B., Chun, F., Mandel, P.}, title = {Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?}, journal = {Chinese Clinical Oncology}, volume = {13}, number = {1}, year = {2023}, url = {https://cco.amegroups.org/article/view/117999} }